Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Therapy
Gefitinib with weekly epirubicin controls disease in patients with metastatic breast cancer
January 26th, 2006
Gefitinib with weekly epirubicin controls disease in patients with metastatic breast cancer. "Epidermal growth factor receptor (EGFR) is overexpressed in approximately 50% of invasive breast carcinomas and it is correlated with hormone resistance and poor prognosis. EGFR suppression by gefitinib, a quinazoline derivative that inhibits phosphorylation of the specific receptor, represents a novel therapeutic strategy," scientists in Italy report. "A dose-finding study was performed to evaluate the combination of gefitinib with weekly epirubicin in patients with pretreated metastatic breast cancer. Fifteen patients were enrolled at four sequential dose...
Source: Women's Health Weekly (2006-01-26)
|
